This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61388980%3A_____%2F12%3A00434359%21RIV15-AV0-61388980/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/resource/domain/vavai/projekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n9http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61388980%3A_____%2F12%3A00434359%21RIV15-AV0-61388980
rdf:type
n14:Vysledek skos:Concept
dcterms:description
The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug. Over the last ten years, the number of poorly soluble drugs has steadily increased. One of the progressive ways for increasing oral bioavaibility is the technique of nanoparticle preparation, which allows many drugs to thus reach the intended site of action. Candesartan cilexetil and atorvastatin, belonging to class II of the biopharmaceutical classification system, were chosen as model active pharmaceutical ingredients in this study. Forty samples were prepared either by antisolvent precipitation/solvent evaporation method or by the emulsion/solvent evaporation technique with various commonly used surface-active excipients as nanoparticle stabilizers. All samples were analyzed by means of dynamic light scattering. The particle size of the determined 36 nanoparticle samples was to 574 nm, whereas 32 samples contained nanoparticles of less than 200 nm. Relationships between solvents and excipients used and their amount are discussed. Based on the results the investigated solvent evaporation methods can be used as an effective and an affordable technique for the preparation of nanoparticles. The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug. Over the last ten years, the number of poorly soluble drugs has steadily increased. One of the progressive ways for increasing oral bioavaibility is the technique of nanoparticle preparation, which allows many drugs to thus reach the intended site of action. Candesartan cilexetil and atorvastatin, belonging to class II of the biopharmaceutical classification system, were chosen as model active pharmaceutical ingredients in this study. Forty samples were prepared either by antisolvent precipitation/solvent evaporation method or by the emulsion/solvent evaporation technique with various commonly used surface-active excipients as nanoparticle stabilizers. All samples were analyzed by means of dynamic light scattering. The particle size of the determined 36 nanoparticle samples was to 574 nm, whereas 32 samples contained nanoparticles of less than 200 nm. Relationships between solvents and excipients used and their amount are discussed. Based on the results the investigated solvent evaporation methods can be used as an effective and an affordable technique for the preparation of nanoparticles.
dcterms:title
Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation
skos:prefLabel
Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation
skos:notation
RIV/61388980:_____/12:00434359!RIV15-AV0-61388980
n3:aktivita
n13:P n13:I
n3:aktivity
I, P(GAP304/11/2246)
n3:cisloPeriodika
11
n3:dodaniDat
n4:2015
n3:domaciTvurceVysledku
n17:3149722
n3:druhVysledku
n15:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n7:predkladatel
n3:idSjednocenehoVysledku
161335
n3:idVysledku
RIV/61388980:_____/12:00434359
n3:jazykVysledku
n18:eng
n3:klicovaSlova
candesartan cilexetil; atorvastatin; nanoparticles; solvent evaporation; excipients; dynamic light scattering
n3:klicoveSlovo
n6:solvent%20evaporation n6:dynamic%20light%20scattering n6:atorvastatin n6:nanoparticles n6:excipients n6:candesartan%20cilexetil
n3:kodStatuVydavatele
CH - Švýcarská konfederace
n3:kontrolniKodProRIV
[A4518188C546]
n3:nazevZdroje
Molecules
n3:obor
n16:CA
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
5
n3:projekt
n8:GAP304%2F11%2F2246
n3:rokUplatneniVysledku
n4:2012
n3:svazekPeriodika
17
n3:tvurceVysledku
Grünwaldová, Veronika Král, V. Dohnal, J. Jampílek, J. Vaculíková, E.
n3:wos
000311428400057
s:issn
1420-3049
s:numberOfPages
14
n9:doi
10.3390/molecules171113221